Vladimir Lisitskiy

Prof. Vladimir Lisitskiy

Institute of Chemical Biology and Fundamental Medicine of SB RAS
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
VLVladimir Lisitskiy
Vladimir Lisitskiy
HKHamda Khan
Hamda Khan
TPTatyana V. Popova
Tatyana V. Popova
Alexey ChubarovAlexey Chubarov
Alexey Chubarov
OZOlga Zakharova
Olga Zakharova
TGTatyana S. Godovikova
Tatyana S. Godovikova

29 October 2021 in Molecules
Verified
Journal Article
Open access
PDF file
TPTatyana Popova
Tatyana Popova
MDMaya A. Dymova
Maya A. Dymova
LKLyudmila S. Koroleva
Lyudmila S. Koroleva
OZOlga Zakharova
Olga Zakharova
VLVladimir Lisitskiy
Vladimir Lisitskiy
TGTatyana S. Godovikova
Tatyana S. Godovikova
Boron neutron capture therapy is a unique form of adjuvant cancer therapy for various malignancies including malignant gliomas. The conjugation of boron compounds and human serum albumin (HSA)—a carrier protein with a long plasma half-life—is expected to extend systemic circulation of the boron compounds and increase their accumulation in human glioma cells. We report on the synthesis of fluorophore-labeled homocystamide conjugates of human serum albumin and their use in thiol-‘click’ chemistry to prepare novel multimodal boronated albumin-based theranostic agents, which could be accumulated in tumor cells. The novelty of this work involves the development of the synthesis methodology of albumin conjugates for the imaging-guided boron neutron capture therapy combination. Herein, we suggest using thenoyltrifluoroacetone as a part of an anticancer theranostic construct: approximately 5.4 molecules of thenoyltrifluoroacetone were bound to each albumin. Along with its beneficial properties as a chemotherapeutic agent, thenoyltrifluoroacetone is a promising magnetic resonance imaging agent. The conjugation of bimodal HSA with undecahydro-closo-dodecaborate only slightly reduced human glioma cell line viability in the absence of irradiation (~30 μM of boronated albumin) but allowed for neutron capture and decreased tumor cell survival under epithermal neutron flux. The simultaneous presence of undecahydro-closo-dodecaborate and labeled amino acid residues (fluorophore dye and fluorine atoms) in the obtained HSA conjugate makes it a promising candidate for the combination imaging-guided boron neutron capture therapy.

16 April 2013 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
TGTatyana S. Godovikova
Tatyana S. Godovikova
VLVladimir Lisitskiy
Vladimir Lisitskiy
NANatalya M. Antonova
Natalya M. Antonova
TPTatyana V. Popova
Tatyana V. Popova
OZOlga Zakharova
Olga Zakharova
VSVladimir N. Sil’nikov
Vladimir N. Sil’nikov